[Ip-health] KEI files affidavit in Indian compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)
krista.cox at keionline.org
Tue Feb 14 09:44:20 PST 2012
KEI files affidavit in Indian compulsory licensing case involving Bayer
patents on cancer drug Sorafenib (Nexavar)
KEI has provided an affidavit in an India compulsory licensing dispute
involving Natco and Bayer, for patents on the cancer drug sorafenib (sold
by Bayer under the brand name Nexavar). The case will test the new Section
84 of the India patent act, and in particular, set a precedent for a
reasonably affordable price. Bayer is currently charging 280430 Indian
rupees for a 30 day supply of Nexavar, which is used to treat kidney and
liver cancer. KEI has some background information on soafenib on the web at
http://keionline.org/drugs, including data on research and development,
orphan drug designations and global pricing.
The KEI affidavit covers three topics: the standards for determining if a
price is reasonably affordable, the research and development that
contributed to the development of sorafenib, and the calculations of a
reasonable royalty for sorafenib.
A pdf of the filing is available here.
Knowledge Ecology International
More information about the Ip-health